JP2004501101A - Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 - Google Patents

Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 Download PDF

Info

Publication number
JP2004501101A
JP2004501101A JP2001583803A JP2001583803A JP2004501101A JP 2004501101 A JP2004501101 A JP 2004501101A JP 2001583803 A JP2001583803 A JP 2001583803A JP 2001583803 A JP2001583803 A JP 2001583803A JP 2004501101 A JP2004501101 A JP 2004501101A
Authority
JP
Japan
Prior art keywords
variant
dose
antibody
her2
her2 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501101A5 (cg-RX-API-DMAC7.html
Inventor
カリギウリ，　マイケル　エイ．
メロポル，　ニール　ジェイ．
シルスカイ，　リチャード　エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2004501101A publication Critical patent/JP2004501101A/ja
Publication of JP2004501101A5 publication Critical patent/JP2004501101A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2001583803A 2000-05-15 2001-05-15 Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 Pending JP2004501101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20428400P 2000-05-15 2000-05-15
US09/855,342 US7306801B2 (en) 2000-05-15 2001-05-14 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
PCT/US2001/015525 WO2001087336A1 (en) 2000-05-15 2001-05-15 Cancer treatments by using a combination of an antibody against her2 and interleukin -2

Publications (2)

Publication Number Publication Date
JP2004501101A true JP2004501101A (ja) 2004-01-15
JP2004501101A5 JP2004501101A5 (cg-RX-API-DMAC7.html) 2008-07-03

Family

ID=26899337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001583803A Pending JP2004501101A (ja) 2000-05-15 2001-05-15 Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置

Country Status (7)

Country Link
US (2) US7306801B2 (cg-RX-API-DMAC7.html)
EP (1) EP1282442A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501101A (cg-RX-API-DMAC7.html)
AU (1) AU2001261569A1 (cg-RX-API-DMAC7.html)
CA (1) CA2408974A1 (cg-RX-API-DMAC7.html)
IL (1) IL152896A0 (cg-RX-API-DMAC7.html)
WO (1) WO2001087336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109395082A (zh) * 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
WO2003062375A2 (en) * 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
AU2003210549A1 (en) * 2002-01-18 2003-09-02 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
EP1531850B1 (en) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
AU2003280442B2 (en) 2002-07-01 2009-02-05 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
EP1758610B1 (en) * 2004-05-20 2012-07-04 ZymoGenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
DE602006021142D1 (de) * 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
ES2440481T3 (es) * 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US20070111906A1 (en) * 2005-11-12 2007-05-17 Milner Jeffrey L Relatively low viscosity transmission fluids
PL2463305T3 (pl) * 2006-01-12 2017-02-28 Alexion Pharmaceuticals, Inc. Przeciwciała przeciw OX-2/CD200 i ich zastosowania
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
CN101522717A (zh) * 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2008279618B2 (en) * 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
NZ601111A (en) 2010-01-11 2014-07-25 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
NZ601580A (en) 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
BR112012017405A2 (pt) 2010-02-18 2018-08-14 Genentech Inc método para aumentar o tempo até a recorrência do tumor em paciente com câncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
KR101453462B1 (ko) * 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
CA2940252C (en) 2014-03-11 2022-10-18 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
HUE054529T2 (hu) 2014-03-11 2021-09-28 Molecular Templates Inc Amino-terminális proximális Shiga toxin A alegység effektor régiókat és sejtcélzó immunglobulin-típusú kötõrégiókat tartalmazó proteinek, amelyek képesek CD38 specifikus kötésére
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US9586056B2 (en) 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
WO2016052971A1 (ko) * 2014-09-30 2016-04-07 가톨릭대학교 산학협력단 유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
EP3325510A2 (en) 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2018140427A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
AU2003210549A1 (en) * 2002-01-18 2003-09-02 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療

Also Published As

Publication number Publication date
US7306801B2 (en) 2007-12-11
US20080159981A1 (en) 2008-07-03
US20020031515A1 (en) 2002-03-14
CA2408974A1 (en) 2001-11-22
AU2001261569A1 (en) 2001-11-26
EP1282442A1 (en) 2003-02-12
WO2001087336A1 (en) 2001-11-22
IL152896A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
KR102624564B1 (ko) 항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
US20020009427A1 (en) Methods of therapy for non-hodgkin's lymphoma
KR100909290B1 (ko) 항암 항체
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
US20030185796A1 (en) Methods of therapy for non-hodgkin's lymphoma
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
JP7448552B2 (ja) がんの併用療法
TWI767139B (zh) 抗ｈｅｒ２抗體藥物偶聯物在治療尿路上皮癌中的用途
KR20080110987A (ko) 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
JP2005538034A (ja) 非ホジキンリンパ腫の治療方法
JP2021523096A (ja) 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画
CN118373896B (zh) 抗pd-1抗体与il-2突变体的双功能融合蛋白
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
US20240199758A1 (en) Method for allowing immune cells infiltration in tumors
US11267898B2 (en) Anti-PODXL antibody MAI1738 and its use for cancer treatment
EP1935431A2 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
CN120204383A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
KR20250029883A (ko) 조합 요법
IL293626A (en) Treatment with site specific her2 antibody-drug conjugates
HK40035107A (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110808